EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

When to Stop Antibiotics in the Critically Ill?

Nathan D Nielsen iD, James T Dean, Elizabeth A Shald iD, Andrew Conway Morris iD, Pedro Povoa iD, Jeroen Schouten iD, Nicholas Parchim

Antibiotics · 18.03.2024 · 13 (3) · 272

DOI: 10.3390/antibiotics13030272 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 18.03.2024. Verfasst von Nathan D Nielsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care and Sleep Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past century, antibiotic usage has skyrocketed in the treatment of critically ill patients. There have been increasing calls to establish guidelines for appropriate treatment and durations of antibiosis. Antibiotic treatment, even when appropriately tailored to the patient and infection, is not without cost. Short term risks—hepatic/renal dysfunction, intermediate effects—concomitant superinfections, and long-term risks—potentiating antimicrobial resistance (AMR), are all possible consequences of antimicrobial administration. These risks are increased by longer periods of treatment and unnecessarily broad treatment courses. Recently, the literature has focused on multiple strategies to determine the appropriate duration of antimicrobial therapy. Further, there is a clinical shift to multi-modal approaches to determine the most suitable timepoint at which to end an antibiotic course. An approach utilising biomarker assays and an inter-disciplinary team of pharmacists, nurses, physicians, and microbiologists appears to be the way forward to develop sound clinical decision-making surrounding antibiotic treatment.

Schlagwörter

Stichwörter der Autor:innen

antibioticsantimicrobial resistancebiomarkersclinical responseduration of therapyfixed duration

Autor:innen und Institutionen

  • Division of Pulmonary, Critical Care and Sleep Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.
  • Section of Transfusion Medicine and Therapeutic Pathology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.
  • Department of Pharmacy, University of New Mexico Hospital, Albuquerque, NM 87131, USA.
  • Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.
  • Division of Immunology, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
  • JVF Intensive Care Unit, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.

ORCID-Profile: Nathan D Nielsen, Elizabeth A Shald, Andrew Conway Morris, Pedro Povoa, Jeroen Schouten

Zitieren

APA

Nielsen, N. D., Dean, J. T., Shald, E. A., Conway Morris, A., Povoa, P., Schouten, J., & Parchim, N. (2024). When to Stop Antibiotics in the Critically Ill?. Antibiotics, 13(3), 272. https://doi.org/10.3390/antibiotics13030272

Vancouver

Nielsen ND, Dean JT, Shald EA, Conway Morris A, Povoa P, Schouten J, et al. When to Stop Antibiotics in the Critically Ill?. Antibiotics. 2024;13(3):272. doi:10.3390/antibiotics13030272

BibTeX
@article{Nielsen2024,
  author = {Nielsen, Nathan D and Dean, James T and Shald, Elizabeth A and Conway Morris, Andrew and Povoa, Pedro and Schouten, Jeroen and Parchim, Nicholas},
  title = {When to Stop Antibiotics in the Critically Ill?},
  journal = {Antibiotics},
  year = {2024},
  volume = {13},
  number = {3},
  pages = {272},
  doi = {10.3390/antibiotics13030272}
}
Kostenlos starten →